> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Jemperli’s Regulatory Review Period Determined
- URL: https://www.fdaweb.com/jemperlis-regulatory-review-period-determined/
- Published: 2024-05-10T12:00:00.000Z
- Updated: 2026-09-14T14:30:37.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156957

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for GlaxoSmithKline’s Jemperli (dostarlimab-gxly), indicated for treating adult patients with mismatch repair deficient recurrent or advanced endometrial cancer. The regulatory review period is 1,919 days, of which 1,428 days occurred during the testing phase and 491 days during the approval phase. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-10361.pdf?ref=fdaweb.com).